As of May 23, 2025, Nautilus Biotechnology Inc (NAUT) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Nautilus Biotechnology Inc's Gross Margin to Peers
To better understand Nautilus Biotechnology Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Nautilus Biotechnology Inc (NAUT) | 7775.20% |
| 10X Genomics Inc (TXG) | 67.91% |
| Illumina Inc (ILMN) | 65.44% |
| Mettler-Toledo International Inc (MTD) | 60.06% |
| Waters Corp (WAT) | 59.47% |
| Agilent Technologies Inc (A) | 54.50% |
Compared to its competitors, Nautilus Biotechnology Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.